ORI Capital
VC Fund
Wan Chai, Hong Kong
ORI Capital is a VC fund in Wan Chai focused on Biotechnology and Health Care. ORI Healthcare Fund L.P. is a US$200 million venture capital fund focused on investing in innovative companies with disruptive technologies in the healthcare industry globally. The fund is founded by Ms. Simone Song, former investment banker and head of China Healthcare at Goldman Sachs. The team consists mostly of former Goldman Sachs bankers andhealthcare scientists. The Fund is supported by a network of most renowned scientists, practitioners and entrepreneurs.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 79%
- Fund size:
- $400M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries ORI Capital invests in
BiotechnologyHealth CareHealth DiagnosticsMedicalBiopharma
Stages ORI Capital invests in
Series BSeries CSeries ASeries DSeries E
Countries ORI Capital invests in
United StatesUnited Kingdom
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Simone Song
|
|||
Investment Focus
Industry
- Biotechnology 7 (50%)
- Health Care 6 (43%)
- Health Diagnostics 4 (29%)
- Medical 3 (21%)
- Biopharma 2 (14%)
Stage
- Series B 4 (29%)
- Series C 3 (21%)
- Series A 2 (14%)
- Series D 2 (14%)
- Series E 1 (7%)
Country
- United States 7 (50%)
- United Kingdom 2 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Simone Song
Senior Partner and Founding Partner
|
Senior Partner and Founding Partner | Total investments: 8 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CG Oncology
|
CG Oncology formerly known as Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies.CG Oncology acquired therights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial. | $120M / Series E / Nov 15, 2022 | |
AffyImmune Therapeutics
|
AffyImmune Therapeutics is a biopharmaceutical company specializing in affinity tuned Chimeric Antigen Receptor (“CAR”) T cell therapy in solid tumors. The Company’s proprietary technology may significantly improve the existing CAR-T cell therapy by extending the target of CAR-T therapies to solid tumors using a novel molecule and tuning down theaffinity from picomolar to micromolar level to lower the on-target off-tumor toxicity. | $20M / Series A / Oct 07, 2021 | |
|
AffyImmune Therapeutics
|
AffyImmune Therapeutics is a biopharmaceutical company specializing in affinity tuned Chimeric Antigen Receptor (“CAR”) T cell therapy in solid tumors. The Company’s proprietary technology may significantly improve the existing CAR-T cell therapy by extending the target of CAR-T therapies to solid tumors using a novel molecule and tuning down theaffinity from picomolar to micromolar level to lower the on-target off-tumor toxicity. | $20M / Series A / Oct 07, 2021 | |
|
CG Oncology
|
CG Oncology formerly known as Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies.CG Oncology acquired therights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial. | $47M / Series D / Dec 10, 2020 | |
Pillar Biosciences
|
Pillar Biosciences is prized with its patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which achieves high sensitivity and specificity with clinical samples. The platform provides a fast, simple and affordable targeted sequencing method for NGS-based oncology testing. The start-up has also released itsbeta version of Lung & Colon Cancer Somatic Mutation Panel and BRCA1 & BRCA2 Germline Mutation Panel to cancer centers and clinical testing companies in the US and China for validation studies.The company was founded in 2014 and is headquartered in Natick, Massachusetts. | $29.7M / Series C / May 12, 2020 | |
|
CG Oncology
|
CG Oncology formerly known as Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies.CG Oncology acquired therights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial. | $22M / Series C / Mar 18, 2019 | |
Enable Injections
|
Enable Injections develops and manufactures wearable drug delivery systems centered on the enFuse platform, a body-worn technology that enables subcutaneous administration of large-volume pharmaceutical and biologic therapies without traditional intravenous methods. The company focuses on engineering devices that allow patients to receive treatmentthrough simple, hands-free injections under the skin while collaborating with pharmaceutical partners to integrate its delivery systems with specific therapies. Its services encompass design, clinical support, manufacturing, and supply of combination products built around the enFuse technology. Enable Injections engages in partnerships to expand application of its delivery systems across varied therapeutic areas and supports regulatory and commercialization planning with its collaborators. | $50M / Series B / Oct 25, 2018 | |
Orchard Therapeutics
|
Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. Theseprograms include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott Aldrich syndrome) and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline.The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London, San Francisco and Boston. | $110M / Series B / Dec 20, 2017 | |
Semma Therapeutics
|
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to SemmaTherapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes. | $114M / Series B / Nov 29, 2017 | |
Arterys
|
Arterys is the market leader and the world's first internet platform for medical imaging. Its objective is to transform healthcare by transforming radiology. The Arterys platform is 100% web-based, AI-powered, and FDA-cleared, unlocking simple clinical solutions. | $30M / Series B / Nov 15, 2017 | |
| See all 14 investments → | |||
Co-Investors
Partisan Management Group
3 deals together
CincyTech
2 deals together
Cintrifuse
2 deals together
Cowen Group
2 deals together
Malin Corporation
2 deals together
Ohio Innovation Fund
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does ORI Capital invest in?
ORI Capital invests primarily in Biotechnology, Health Care and Health Diagnostics startups, most often at Series B and Series C stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact ORI Capital?
Public channels for ORI Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ORI Capital?
The team at ORI Capital includes Simone Song (Senior Partner and Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
